ISSN:
1569-8041
Keywords:
anti CD-20 antibody
;
follicular lymphoma
;
immunotherapy
;
mantle-cell lymphoma
;
Rituximab
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Background:Clinical activity of the anti CD-20 monoclonalantibody Rituximab has been reported in patients with follicular lymphoma (FL)and mantle-cell lymphoma (MCL). Patients and methods:120 patients with bi-dimensionallymeasurable FL or MCL (R.E.A.L. Classification) were treated with Rituximab 375mg/m2/week for 4 weeks. A central pathology review confirmed thediagnosis of FL in 76 of 78 and of MCL in 39 of 42 cases. The response wasevaluated after 8 weeks and confirmed after 12 weeks from the start oftreatment. Results:The toxicity of the treatment was, as expected, grade1–2 fever and rigors during the first infusion and mild asthenia duringthe treatment period. Serious adverse events, probably or possibly related tothe study treatment, included four deaths (3 of cardiac origin, 1 caused byP. cariniipneumonia) and 10 further nonfatal cases, including apermanent agranulocytosis and one case of heart failure. Response rate at week12 was 52% for FL and 22% for MCL. After treatment, theBCL-2rearrangement disappeared in 15 of 29 blood but only in 5 of23 bone marrow samples; BCL-1disappeared in 5 of 12 blood and 0 of7 bone marrow specimens, as determined by PCR. Conclusions:Rituximab is an active agent for the treatment of FL,while its efficacy is modest in MCL. The effect in reducing minimal residualdisease is more pronounced on the blood than it is on the bone marrow.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1023/A:1008301432453
Permalink